top of page
Tackling the Serious Global Challenges in Infectious Disease
Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases
Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.
Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization
Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives
LATEST NEWS RELEASES
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
1/17/2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
1/13/2023
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
LATEST EVENTS
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
1/17/2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
1/13/2023
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/15/2022
bottom of page